Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. - Wikidata - awgldk - TriplyDB

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

http://www.wikidata.org/entity/Q37685847

about

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes Newer agents in antiplatelet therapy: a review.Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndrome Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.Modern antiplatelet agents in coronary artery disease.Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.Health-related quality of life in patients with acute coronary syndromes and treated with ticagrelor or clopidogrel.Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.

P2860

Q24605508-8FB4340E-A51B-4A0C-B874-E5464A316473 Q24631111-F61830B9-32A2-40BD-94EE-E81FF3D7A2F8 Q36085620-72B72636-7E77-4890-9A5B-B45ECFE30635 Q36327413-44896A7D-7D70-450C-B13E-CBC63FF98F6C Q37692142-72800F50-6D7E-452F-8D7E-83AE10434FC6 Q37925007-9A73FCEC-5FCF-4C85-8960-7580EA582799 Q38063289-B281B319-FFD9-47B9-979D-623C7F093E58 Q39635786-CA2800D9-565E-4554-924F-93A036197CF0 Q39766399-F6E6E8DA-B177-43E7-9C45-8D26ABAA2EEF Q41511099-CAFDB963-C2DE-47C6-8485-E60AF89AA656 Q42748476-C7623043-F03F-4749-858B-F6A919AA9ACB Q45880249-109F589D-EE00-4759-899D-CFC880382262 Q55444892-D918D967-47F8-4253-B34A-08380D34BC0F

P2860

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

http://www.wikidata.org/entity/Q37685847

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 February 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

@en

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

@nl

type

label

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

@en

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

@nl

prefLabel

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

@en

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

@nl

P1433

Q37685847-08078825-2451-4A0F-BBA8-81FB10CDCB0D

P1476

Q37685847-4D1184ED-FF92-4251-9591-1BA48E505C78

P2093

Q37685847-17E5BA07-0084-46C6-BACD-56E9D06842EB

Q37685847-8EAACDB6-CE03-4B4F-84A2-9B4D90A75E73

Q37685847-BCD184A5-F85E-4524-B0A1-4603B661AB5B

Q37685847-DEEA68F4-8A21-4F94-8CFA-9BA573985FFA

P2860

Q37685847-000BD8F5-BF34-4D9F-BFF6-0D33BAA6F584

Q37685847-16656D74-812F-4339-9E1F-3C51D7210875

Q37685847-1A3E1914-E6D0-4613-A297-B0672E8D4CFA

Q37685847-22F70AF2-BB55-481F-9293-EB025D8EA6BE

Q37685847-23FD7A04-B63F-4B50-802F-876006FED5CA

Q37685847-2C6BD413-BDA6-42D8-9FC2-107642D3DA02

Q37685847-2FA40F12-DA91-4CA7-8E9C-4B21335D99E3

Q37685847-317AF243-1A4F-4A0E-9B5D-D4537F03C89C

Q37685847-46B0C734-7B93-4ACD-92DE-8CD573A17DD6

Q37685847-48340EB4-B526-4E63-A338-6C424056CB44

P304

Q37685847-E3D641CA-9AB7-4985-884E-516B9EC19A54

P31

Q37685847-CCA9D696-3822-48AC-B0D5-593DE2206625

P356

Q37685847-2CE00690-E23F-4A3C-962A-0CA967575E49

P407

Q37685847-D8627173-D90C-4BB8-A0AF-2A6000F6B16D

P433

Q37685847-2D898DAF-FCD1-46BD-A856-E46DDED86A91

P478

Q37685847-6B7EA06E-1CCA-4425-B9CB-B644427145CD

P577

Q37685847-C9C800DC-F223-4B9D-A61C-6BDDC9CC4C4F

P698

Q37685847-5BE06A51-3750-41D8-A27D-1B0B1FCEBD85

P356

P1433

Annals of Pharmacotherapy

P1476

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

@en

P2093

Benjamin J Epstein

http://www.w3.org/2001/XMLSchema#string

Juwon Yim

http://www.w3.org/2001/XMLSchema#string

Niren K Shah

http://www.w3.org/2001/XMLSchema#string

Shawn D Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Adenosine receptors as therapeutic targets

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel

P304

524-537

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1M548

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20124464

http://www.w3.org/2001/XMLSchema#string